Ask The Board

  1. It Seems The High Cost Of Drug Development Is Unsustainable. Should New Regulatory Pathways Be Considered?

    See the answer from Tom DiLenge, president, advocacy, law & public policy division for the Biotechnology Innovation Organziation (BIO).

  2. What Is Your Opinion On The Present Reimbursement Landscape In U.S. Healthcare?

    See the answer from Paul Hastings, CEO of Nkarta Therapeutics. He has over 30 years of biopharmaceutical industry experience.

  3. How Can We Ensure We Don't Overburden Patients With Requests For Input Into Our Trial Designs And Disease Burden Questions?

    See the answer from Margaret Anderson, a managing director at Deloitte. She was previously Executive Director at FasterCures, a center of the Milken Institute.

  4. How Do You Mitigate The Risks To Patient Safety And Data Integrity In Virtual Clinical Trials?

    See the answer from Al Altomari, chairman and CEO of Agile Therapeutics.

  5. How Are Life Science Leaders Preparing For A Potential Talent Shortage In The New Digital World?

    See the answer from Chhaya Shah, SVP of technical operations at Radius Health.

  6. Do You Think The Biopharma Industry Is Prepared For Brexit, And What Impact Will It Have On The Industry?

    See the answer from Allan Shaw, a four-time public company CFO who has served on five public boards, which included chairing two audit committees and two compensation committees.

  7. As Governments Develop Policies And Regulatory Guidelines Around AI, What Advice Do You Have For Pharma Leaders On AI Implementation?

    See the answer from David Pyott, the chairman of Bioniz Therapeutics, a biopharma startup in Irvine, CA. He is the former CEO of Allergan.

  8. What Role Should The Pain Therapeutics Industry Play In Combatting The Opioid Epidemic?

    See the answer from Mitchell Katz, Ph.D., who has 30 years’ experience in the pharma and biotech. He is VP of development operations at Ferring Pharmaceuticals.

  9. How Do You View The Emerging Field Of Anti-Aging Therapies? Is This Therapeutic Approach Ready Now, Five Years Away, Or A Pipe Dream?

    See the answer from Sesha Neervannan, Ph.D., SVP of pharmaceutical development at Allergan.

  10. Over The Next Few Years, Should Biopharmas Broaden Their Definition For What They Define As “Core?”

    See the answer from Joseph Ferra, CFO of Syros Pharmaceuticals.